Successful Treatment of Prostatic Cancer with the Orally Active Depot Estrogen Ethinylestradiol Sulfonate (Turisteron®)

G. Dörner; D. Schnorr; F. Stahl; W. Rohde

doi:10.1055/s-0029-1210486

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000017.xml

Share / Bookmark

Facebook Linkedin Weibo

Download PDF

Exp Clin Endocrinol Diabetes 1985; 86(5): 190-196
DOI: 10.1055/s-0029-1210486

Original

Successful Treatment of Prostatic Cancer with the Orally Active Depot Estrogen Ethinylestradiol Sulfonate (Turisteron^®)

G. Dörner, D. Schnorr, F. Stahl, W. Rohde

Institute of Experimental Endocrinology (Director: Prof. Dr. G. Dörner) and Department of Urology (Director: Prof. Dr. M. Mebel), Humboldt University Medical School (Charité), Berlin/GDR

Further Information

Publication History

1984

Publication Date:
16 July 2009 (online)

Also available at

PDF Download Permissions and Reprints

Summary

Ethinylestradiol sulfonate (Turisteron^®) is an orally highly active depot-estrogen with relatively low side effects. In men with prostatic cancer, weekly administration of 2 mg Turisteron resulted in a striking decrease of the biologically active free testosterone level to less than 2% of the basal level; i.e., even significantly lower than after orchidectomy. Turisteron was able to normalize the 5 year survival rate in men with advanced non-metastatic cancer (T₃N_xM₀) and to increase the survival rate significantly in men with metastatic cancer (T_3-4, N_x, M₁). Hence, due to our experience, Turisteron treatment is a very effective, non-expensive and well tolerated therapy for prostatic cancer.

Key words

Ethinylestradiol sulfonate - Orchidectomy - Radiotherapy - Prostatic cancer